Positive for BOT, page-111

The chart looks good for BOT and so do the fundamentals for this quarter. Raise flippers have been soaked nicely over the past month.

IND FDA submission for the lead product along with Phase 1B results from their atopic dermatitis study this quarter leads me to believe we will be over 20c come June as long as the results are positive.

With all the promising properties CBD address as well as BOT using a placebo in the dermatitis study tells me its a safe bet.